Based on the results of the retrospective patient cohort evaluation, indicating that anti-CTLA4 acts protectively against lymphedema in patients, and the confirmation of increased CTLA4 expression and increased Treg infiltration in human lymphedema biopsies, CTLA4 was assessed as a potential target in lymphedema pathophysiology. The gene discussed is CTLA4; the disease is lymphedema.